FIM
VRTX icon

FWL Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

FWL Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Hold
30
– – ﹤0.01% 279
2026
Q1 		$13.4K Hold
30
– – ﹤0.01% 243
2025
Q4 		$13.6K Hold
30
– – ﹤0.01% 249
2025
Q3 		$11.7K Hold
30
– – ﹤0.01% 237
2025
Q2 		$13.4K Sell
30
-15
-33% -$6.91K ﹤0.01% 212
2025
Q1 		$21.8K Sell
45
-15
-25% -$6.99K 0.01% 188
2024
Q4 		$24.2K Hold
60
– – 0.01% 192
2024
Q3 		$27.9K Hold
60
– – 0.01% 157
2024
Q2 		$28.1K Buy
60
+15
+33% +$6.51K 0.01% 141
2024
Q1 		$18.8K Hold
45
– – 0.01% 139
2023
Q4 		$18.3K Buy
+45
New +$16.6K 0.01% 135

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

FWL Investment Management's VRTX Position: Q2 2026 in Review

FWL Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 30 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #279.

FWL Investment Management first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $28.1K in Q2 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • FWL Investment Management held 30 shares of Vertex Pharmaceuticals worth $14.9K as of Q2 2026.
  • FWL Investment Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of FWL Investment Management's portfolio in Q2 2026, its #279 holding.
  • FWL Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • FWL Investment Management's Vertex Pharmaceuticals position peaked at $28.1K in Q2 2024.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on FWL Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.